ASBMR: Experimental Compound Boosts Bone Density

Sclerostin-blocking agent looks promising in monkey study

FRIDAY, Sept. 22 (HealthDay News) -- An experimental compound that blocks the activity of sclerostin, a protein secreted by osteocytes, seems to generate new bone growth and strengthen existing bone in monkeys, according to research presented at the 28th annual meeting of the American Society for Bone and Mineral Research in Philadelphia.

Chris Paszty, Ph.D., of Amgen, Inc. in Thousand Oaks, Calif., and colleagues analyzed the effects of the new compound, an anti-sclerostin monoclonal antibody, on female cynomolgous monkeys aged 3 to 5 years.

The compound was injected subcutaneously once a month for two months. The short-term administration of the drug increased bone formation, bone mineral density and vertebral bone strength, the researchers reported.

"The agent used in these studies represents a novel treatment strategy and could lead to a reduced risk of fractures in patients with osteoporosis," said Steve Goldring, M.D., president-elect of the ASBMR, in a statement.


Physician's Briefing